ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2a-ready Cholesterol Efflux MediatorTM VAR 200. Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $75 billion1,2.

IC 100 is a novel inflammasome inhibitor targeting ASC. By targeting ASC, IC 100 inhibits 12 or more types of inflammasomes rather than just one (e.g. NLRP3) to treat multiple CNS and other inflammatory diseases. IC 100 inhibits intracellular ASC to block inflammasome formation and initiation of the inflammatory cascade. It also inhibits intra- and extracellular ASC specks to block perpetuation of damaging inflammation associated with inflammatory diseases.

The active ingredient in Cholesterol Efflux Mediator VAR 200 is 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), demonstrated in preclinical studies to promote cholesterol removal from podocytes, a component of the kidneys’ filtering system, slowing progression of podocyte injury and reducing protein in the urine (proteinuria) that can lead to renal failure.

VAR 200 is in development for focal segmental glomerulosclerosis (FSGS), a rare kidney disease, with potential for development in Alport syndrome and diabetic kidney disease.

ZyVersa’s accomplished leadership team has deep pharmaceutical experience and a successful track record in R&D, commercialization, licensing, M&A, raising capital, and taking companies public. A key focus is assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.


  1. Chronic Kidney Disease Drugs Market Analysis. Coherent Market Insights, November 2020
  2. Anti-Inflammatory Biologics Market Size, Share & Industry Analysis. Fortune Business Insights, May 2020